Search

The article discusses the ethical and legal considerations surrounding the use of artificial intelligence (AI) in global health dermatology. The implementation of AI in low-to-middle-income countries (LMICs) raises concerns about bias, data diversity, and the potential propagation of harmful content. Patient consent and protection from exploitation are important considerations when developing diverse datasets. Ownership and financial benefits derived from health data are also discussed, as well as the legal implications and responsibility for inaccurate diagnoses. The article suggests comprehensive guidelines, local expertise, and standardized training as key areas of focus to address these challenges and ensure the ethical integration of AI in global health dermatology. [Extracted from the article]

We present a 53-year-old woman with severe lichenoid dermatitis secondary to pembrolizumab therapy that was refractory to both topical and oral steroids. After almost three months without improvement, the rash was effectively combated with a single 15mg dose of methotrexate. We hope this case will help guide the management of the cutaneous adverse effects of anti-PD1 immunotherapy. [ABSTRACT FROM AUTHOR]